Clinical trials: Elderly Infection
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years
A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years.
- Trial name
- NCT07300644
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 3 sites in China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Tuberculosis
Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults
This study will assess the safety and immunogenicity of 2 different formulations of tuberculosis vaccine GSK692342 in healthy adults.
- Trial name
- NCT00397943
- Testing
- GSK's candidate Mycobacterium tuberculosis vaccine 692342, Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system, Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline
- Where
- Belgium
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic when given to adults aged 18-64 years.
- Trial name
- NCT00771615
- Testing
- GSK A/turkey H5N1 Influenza vaccine
- Where
- 10 sites in United States, Canada
- Volunteers
- 469 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus (RSV)
Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine （CHO Cell） in Adults Aged 18 Years and Older
This phase 1 study in China will evaluate the Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older
- Trial name
- NCT07807449
- Testing
- Recombinant RSV Vaccine (CHO Cell), Adjuvant Suspension, Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Yikang Biotech (Suzhou) Co., Ltd.
COVID-19 Pneumonia, COVID-19
Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above
This is a open label clinical trial to evaluate the efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines (Vero cell) in healthy people aged 3-17 years old in comparison with healthy population aged 18 years old…
- Trial name
- COVID-19 (NCT04917523)
- Testing
- SARS-CoV-2 Vaccine (Vero Cell), Inactivated
- Where
- United Arab Emirates
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT02381418
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abbott
SARS-CoV-2, COVID-19
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
The purpose of this post-marketing study is to assess the safety of Comirnaty monovalent XBB.1.5. for booster vaccination children ages 6 months though 4 years under actual use medical practice.
- Trial name
- NCT06130410
- Testing
- COMIRNATY intramuscular injection
- Where
- Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older
This Expanded Access, Phase 3, open label study is intended to provide access to COVAXIN™ (BBV152) to individuals who are at risk or have predisposing conditions that can lead to complications with the current immunization…
- Trial name
- NCT05541289
- Testing
- BBV152
- Where
- United States
- Sponsor
- Ocugen
Encephalitis, Tick-borne
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all subjects who completed two vaccinations in one of the three…
- Trial name
- NCT00161850
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 25 sites in Austria, Germany
- Volunteers
- 615 people, healthy volunteers welcome
- Sponsor
- Pfizer
Community-acquired Pneumonia (CAP), Hospital-acquired Pneumonia (HAP)
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired…
- Trial name
- NCT03439124
- Testing
- ceftobiprole medocaril, IV standard-of-care cephalosporin
- Where
- 19 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 138 people
- Sponsor
- Basilea Pharmaceutica
Influenza, Human
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately 7700 male and female adults aged 50 years and older (approximately equally…
- Trial name
- NCT06015282
- Testing
- Investigational aQIVc, licensed QIVr, licensed aQIV
- Where
- 96 sites in United States, Canada and 6 more
- Volunteers
- 7,741 people, healthy volunteers welcome
- Sponsor
- Seqirus
Community-Acquired Bacterial Pneumonia (CABP)
Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia
The purpose of this study is to determine the safety and efficacy of ceftaroline fosamil in elderly subjects with community-acquired bacterial pneumonia (CABP) receiving antibiotic therapy in the hospital.
- Trial name
- NCT01666743
- Testing
- Ceftaroline fosamil
- Sponsor
- Forest Laboratories
COVID - 19
PA-001 Ph.1 Study in Healthy and Elderly Subjects
This was a double blind, randomized, placebo controlled, single and multiple IV dose study conducted in 2 parts, single ascending dose and multiple ascending doses parts.
- Trial name
- NCT07518771
- Testing
- PA-001
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- PeptiDream Inc.
Genital Wart, Penile Cancer
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Human Papillomavirus (HPV) Recombinant Vaccine (Hansenula Polymorpha) in Chinese male…
- Conditions
- Genital Wart, Penile Cancer, Anal Cancer, PIN-1
- Trial name
- NCT06465914
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- 5 sites in China
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Influenza A
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection
The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.
- Trial name
- NCT03376321
- Testing
- Pimodivir 600 mg, SOC Treatment
- Where
- 269 sites in United States, Argentina and 36 more
- Volunteers
- 334 people
- Sponsor
- Janssen Research & Development, LLC
Influenza, Human
A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older
The purpose of this study is to evaluate immunological efficacy and safety of GC3110A among healthy adults over 65 years of age.
- Trial name
- NCT02917304
- Testing
- GC3110A vaccine
- Where
- 10 sites in South Korea
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine
The aim of the study is to to assess the immunogenicity and safety of a quadrivalent influenza vaccine in a multi-dose presentation compared to a quadrivalent influenza vaccine in single-dose presentation, in children aged 6…
- Trial name
- NCT03391193
- Testing
- Multi-dose Quadrivalent Influenza Vaccine, Single-dose Quadrivalent Influenza Vaccine
- Where
- 3 sites in Mexico
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Herpes Zoster
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
The purposes of the study are to evaluate the immunogenicity and safety of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 30 years and older.
- Trial name
- NCT05856084
- Testing
- Low dose Recombinant Herpes Zoster Vaccine (CHO cells), High dose Recombinant Herpes Zoster Vaccine (CHO cells), Positive control
- Where
- China
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Herpes Simplex
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
Main goal of this study is to compare the occurrence of serious adverse events (SAEs) between the herpes simplex (gD2-AS04) vaccine group and the Saline control group throughout the study period (up to month 12).
- Trial name
- NCT00224484
- Testing
- GSK208141, Havrix (investigational formulation)
- Where
- 151 sites in United States, Australia and 16 more
- Volunteers
- 5,960 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose)
This is a randomized, double-blind, active-controlled Phase I clinical trial to evaluate the safety and immunogenicity of Influenza Vaccine (Split Virion), Inactivated (High Dose) developed by Sinovac.
- Trial name
- NCT07737106
- Testing
- Influenza Vaccine (Split Virion), Inactivated (High Dose), Influenza Vaccine (Split Virion), Inactivated
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.